- Report
- June 2025
- 235 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 287 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- April 2025
- 175 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- May 2025
- 150 Pages
Global
From €2417EUR$2,699USD£2,061GBP
- Report
- July 2024
- 231 Pages
Global
From €7121EUR$7,950USD£6,070GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3359EUR$3,750USD£2,863GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1791EUR$2,000USD£1,527GBP
- Report
- February 2025
- 183 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- May 2024
- 391 Pages
Global
From €5282EUR$6,103USD£4,350GBP
- Report
- October 2023
- 85 Pages
United States
From €4344EUR$4,850USD£3,703GBP
- Report
- October 2022
- 270 Pages
Global
From €3359EUR$3,750USD£2,863GBP
- Report
- May 2024
- 133 Pages
Global
From €5821EUR$6,499USD£4,962GBP
- Report
- May 2024
- 133 Pages
Global
From €5821EUR$6,499USD£4,962GBP
- Report
- May 2024
- 137 Pages
Global
From €5821EUR$6,499USD£4,962GBP
- Report
- May 2024
- 130 Pages
Global
From €5821EUR$6,499USD£4,962GBP
- Report
- May 2024
- 138 Pages
Global
From €5821EUR$6,499USD£4,962GBP
- Report
- August 2022
- 118 Pages
Global
From €4031EUR$4,500USD£3,436GBP
- Report
- September 2021
- 111 Pages
Global
From €4031EUR$4,500USD£3,436GBP
- Report
- May 2024
- 200 Pages
Global
From €3717EUR$4,150USD£3,169GBP
- Report
- February 2022
- 210 Pages
Global
From €6718EUR$7,500USD£5,726GBP

Etanercept is a biologic drug used to treat immune disorders such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It is a recombinant fusion protein that works by blocking the action of tumor necrosis factor (TNF), a protein involved in inflammation. Etanercept is administered by subcutaneous injection and is available in both brand name and generic forms.
Etanercept is a widely used drug in the treatment of immune disorders, and is often prescribed in combination with other medications. It is generally well tolerated, with the most common side effects being injection site reactions, headache, and upper respiratory tract infections.
The etanercept market is highly competitive, with several major players. These include Amgen, Pfizer, AbbVie, and Johnson & Johnson. Other companies in the market include Biogen, Merck, and Novartis. Show Less Read more